Working Together for the Greater Good: The Current State of the Collaborative Research Ecosystem in Oncology

06.12.14 | By

Keeping the spirit of innovation alive in the oncology field is paramount to future scientific advances and finding cures. An essential element of innovation is collaboration. Relevant stakeholders coming together and pooling collective knowledge together can ignite the fire that becomes the next big thing to improve the lives of cancer patients.

Some Health Insurance Exchange Plans Put All Treatments for Certain Diseases on Top Cost-Sharing Tier

06.11.14 | By

This morning at the National Press Club, PhRMA CEO John J. Castellani joined patient groups to release new research from Avalere Health.

Broader Discussion on Cancer Care Spending Needed

06.10.14 | By

If we want to have an honest discussion around cost, we must do so in a way that includes the entire spectrum of cancer care and not focused solely on the cost of cancer medicines.

A Look at What Is Coming Through the Pipeline for Cancer Research: A Q&A with Astellas’ Josh Schafer

06.09.14 | By

With the recent conclusion of ASCO, we sat down with Josh Schafer, Astellas’ Vice President of Oncology Marketing Strategy, to get his perspective on the current state of affairs surrounding cancer research.

Increased Collaboration and Investment in Science and Regulatory Workforce Necessary to Advance Scientific Discovery

06.09.14 | By

PhRMA strongly supports the goals of the House Energy and Commerce Committee’s 21st Century Cures initiative that seeks to accelerate the discovery, development and delivery of new treatments and potential cures to patients.

Canada’s IP Policies Need New Look

06.06.14 | By

The current intellectual property (IP) environment in Canada has caused increased friction with its closest allies, particularly in the area of IP rights protections for biopharmaceutical products. By revoking 19 patents since 2005 through questionable decisions, Canadian courts have set a disturbing precedent that risks future investments in cutting-edge R&D projects in innovative industries, and the high-paying jobs that accompany them.

Week in Review: The Price of Innovation & Patient Well-Being

05.30.14 | By

The cost of innovative new medicines to treat devastating diseases such as cancer and Hepatitis C has been a hot discussion topic this week. A critical part of this discussion – the value of these treatments – however, has been overlooked. As our President and CEO John Castellani said, focusing solely on the cost of a new treatment and ignoring its subsequent value is “penny wise and pound foolish” because prescription medicines provide patients and the health care system long-term cost savings.

Achieving the shared goal of bringing safe and effective new medicines to patients

05.30.14 | By

Each patient facing a life-threatening disease lives with the hope that tomorrow will bring a new medicine to extend and improve his or her life.  As a scientist, a new father, and as someone who lost a parent to stage IV lung cancer far too early in life, it is gut-wrenching to admit that modern drug development continues to be a highly challenging and far too often unsuccessful endeavor. 

Transforming Healthcare One Employee at a Time

05.30.14 | By

Businesses know the impact of poor health and see first hand how some communities are affected more than others. Truly improving health takes time, effort and investment from all of us. With one out of two Americans having at least one chronic condition, the costs of chronic disease are staggering and affect every community, every business, and every person.

The Global Impact of Innovative Medicines

05.23.14 | By

Across our health care system, it’s critical that patients always remain at the center of our shared efforts to improve, extend and save lives. For PhRMA and the industry writ-large, this is a bedrock mindset and ongoing access to innovative medicines represents health care’s best shot at preventing and managing costly chronic diseases. This week, we focused on the importance of patient access – along with safety – both in the United States and around the globe.

Pages

Subscribe to RSS - Opinion